How Can US FDA Bolster Drug Development? The Agency Wants Your Advice
Public meeting scheduled for November to seek recommendations for policies that FDA could implement short-term to promote drug development programs.
You may also be interested in...
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.
Center for Drug Evaluation and Research Director Janet Woodcock continues to promote innovation in clinical trial design with a review of master protocols in the New England Journal of Medicine.
Agency anticipated receiving more applications for the program, which aims to bring Operation Warp Speed-like response to investigational rare disease therapies, than it has so far, though a last-minute ‘flood’ is still expected. CBER and CDER are accepting requests through 1 March.